RNS Number : 2789K Renalytix PLC 31 August 2021 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this
RNS Number : 2775K Renalytix PLC 31 August 2021 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered
RNS Number : 2097K Renalytix PLC 31 August 2021 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered
RNS Number : 1082K Renalytix PLC 31 August 2021 Renalytix plc (" Renalytix " or the " Company ") Renalytix Appoints Daniel J. Levangie to its Board of Directors Levangie brings extensive commercial operating experience to Renalytix, served on boards of Exact Sciences, Insulet Corporation
Levangie brings extensive commercial operating experience to Renalytix, served on boards of Exact Sciences, Insulet Corporation and Hologic NEW YORK and SALT LAKE CITY, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced the appointment of Daniel J.
Peer reviewed publication in Journal of Medical Economics supports payer coverage for early-stage risk assessment and care management in the primary care office NEW YORK and SALT LAKE CITY, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced the publication of
RNS Number : 8163J Renalytix PLC 26 August 2021 Renalytix plc (" Renalytix " or the " Company ") Payer Budget Impact Analysis Projects Significant Savings from KidneyIntelX TM Testing at Primary Care Level Peer reviewed publication in Journal of Medical Economics supports payer coverage for
RNS Number : 6311I Renalytix PLC 13 August 2021 Renalytix plc (" Renalytix " or the " Company ") Director/PDMR Dealing New York , 13 August 2021 - Renalytix (LSE: RENX) announces that it has been advised of the sale by O. James Sterling , the Company's Chief Financial Officer, of 12,000
RNS Number : 9108H Renalytix PLC 06 August 2021 Renalytix plc (" Renalytix " or the " Company ") Director/PDMR Dealing New York , 6 August 2021 - Renalytix (LSE: RENX) announces that it has been advised of the sale by O. James Sterling , the Company's Chief Financial Officer, of 12,000
RNS Number : 2696H Renalytix PLC 02 August 2021 Renalytix plc (" Renalytix " or the " Company ") Total voting rights New York , 2 August 2021 - Renalytix (LSE: RENX) announces that t he Company's total issued share capital consists of 72,229,786 shares of 0.25 pence each, with each
